Procter & Gamble Health Limited (BOM:500126)
India · Delayed Price · Currency is INR 6,781.40
+57.80 (0.86%)
At close: Jul 27, 2026
Procter & Gamble Health Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
| 14,080 | 12,181 | 11,513 | 12,296 | 11,144 | |
Revenue Growth | 15.59% | 5.80% | -6.37% | 10.34% | 10.48% |
Cost of Revenue | 3,651 | 3,490 | 3,425 | 3,834 | 3,531 |
Gross Profit | 10,429 | 8,691 | 8,087 | 8,463 | 7,614 |
Selling, General & Admin | 2,226 | 2,333 | 2,682 | 2,811 | 2,776 |
Other Operating Expenses | 3,637 | 2,689 | 2,340 | 2,412 | 2,141 |
Operating Expenses | 6,098 | 5,260 | 5,296 | 5,504 | 5,188 |
Operating Income | 4,331 | 3,431 | 2,791 | 2,959 | 2,426 |
Interest Expense | -5.5 | -6.3 | -7.2 | -7.7 | -4.2 |
Interest & Investment Income | - | 70.4 | 117.3 | 143.3 | 110.7 |
Currency Exchange Gain (Loss) | - | -1.6 | 2.7 | 3.4 | -6.9 |
Other Non Operating Income (Expenses) | 173.4 | 54.4 | 36.3 | 30.1 | 21.2 |
EBT Excluding Unusual Items | 4,499 | 3,548 | 2,940 | 3,128 | 2,546 |
Merger & Restructuring Charges | - | - | -201.9 | - | - |
Gain (Loss) on Sale of Assets | - | -1.3 | -5.1 | 7.1 | -5.4 |
Asset Writedown | - | - | - | 7.3 | -7.3 |
Other Unusual Items | - | -201.9 | - | - | - |
Pretax Income | 4,499 | 3,345 | 2,733 | 3,142 | 2,534 |
Income Tax Expense | 1,230 | 832.6 | 723.4 | 847.3 | 608.5 |
Earnings From Continuing Operations | 3,269 | 2,512 | 2,010 | 2,295 | 1,925 |
Net Income | 3,269 | 2,512 | 2,010 | 2,295 | 1,925 |
Net Income to Common | 3,269 | 2,512 | 2,010 | 2,295 | 1,925 |
Net Income Growth | 30.14% | 24.98% | -12.42% | 19.19% | 8.89% |
Shares Outstanding (Basic) | 17 | 17 | 17 | 17 | 17 |
Shares Outstanding (Diluted) | 17 | 17 | 17 | 17 | 17 |
Shares Change | 0.00% | -0.00% | - | - | - |
EPS (Basic) | 196.94 | 151.33 | 121.08 | 138.24 | 115.98 |
EPS (Diluted) | 196.94 | 151.11 | 121.00 | 138.00 | 115.98 |
EPS Growth | 30.33% | 24.89% | -12.32% | 18.99% | 8.89% |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Free Cash Flow | 3,223 | 2,135 | 2,066 | 1,935 | 1,316 |
Free Cash Flow Per Share | 194.15 | 128.63 | 124.44 | 116.58 | 79.28 |
Dividend Per Share | 155.000 | 166.667 | 110.000 | 95.000 | 52.500 |
Dividend Growth | -7.00% | 51.52% | 15.79% | 80.95% | 31.25% |
Gross Margin | 74.07% | 71.35% | 70.25% | 68.82% | 68.32% |
Operating Margin | 30.76% | 28.17% | 24.24% | 24.06% | 21.77% |
Profit Margin | 23.22% | 20.62% | 17.46% | 18.66% | 17.28% |
Free Cash Flow Margin | 22.89% | 17.53% | 17.94% | 15.74% | 11.81% |
EBITDA | 4,567 | 3,621 | 3,034 | 3,188 | 2,648 |
EBITDA Margin | 32.43% | 29.73% | 26.36% | 25.92% | 23.76% |
D&A For EBITDA | 235.9 | 190.13 | 243 | 229 | 222.1 |
EBIT | 4,331 | 3,431 | 2,791 | 2,959 | 2,426 |
EBIT Margin | 30.76% | 28.17% | 24.24% | 24.06% | 21.77% |
Effective Tax Rate | 27.33% | 24.89% | 26.47% | 26.97% | 24.02% |
Revenue as Reported | 14,253 | 12,305 | 11,669 | 2,480 | 11,276 |
Advertising Expenses | - | - | 526.5 | 744.9 | 1,095 |